285 related articles for article (PubMed ID: 34406395)
21. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
22. Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
Schopman JE; Hoekstra JBL; Frier BM; Ackermans MT; de Sonnaville JJJ; Stades AM; Zwertbroek R; Hartmann B; Holst JJ; Knop FK; Holleman F
Diabetes Obes Metab; 2015 Jun; 17(6):546-553. PubMed ID: 25694217
[TBL] [Abstract][Full Text] [Related]
23. DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: A PILOT RANDOMIZED STUDY.
Ferjan S; Janez A; Jensterle M
Endocr Pract; 2018 Jan; 24(1):69-77. PubMed ID: 29144805
[TBL] [Abstract][Full Text] [Related]
24. Hypoglycemia and Islet Dysfunction Following Oral Glucose Tolerance Testing in Pancreatic-Insufficient Cystic Fibrosis.
Kilberg MJ; Harris C; Sheikh S; Stefanovski D; Cuchel M; Kubrak C; Hadjiliadis D; Rubenstein RC; Rickels MR; Kelly A
J Clin Endocrinol Metab; 2020 Oct; 105(10):3179-89. PubMed ID: 32668452
[TBL] [Abstract][Full Text] [Related]
25. Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.
Kelly A; De Leon DD; Sheikh S; Camburn D; Kubrak C; Peleckis AJ; Stefanovski D; Hadjiliadis D; Rickels MR; Rubenstein RC
Am J Respir Crit Care Med; 2019 Feb; 199(3):342-351. PubMed ID: 30130412
[TBL] [Abstract][Full Text] [Related]
26. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.
Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD
Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258
[TBL] [Abstract][Full Text] [Related]
27. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation.
Kuo P; Stevens JE; Russo A; Maddox A; Wishart JM; Jones KL; Greville H; Hetzel D; Chapman I; Horowitz M; Rayner CK
J Clin Endocrinol Metab; 2011 May; 96(5):E851-5. PubMed ID: 21389144
[TBL] [Abstract][Full Text] [Related]
28. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.
Muscelli E; Casolaro A; Gastaldelli A; Mari A; Seghieri G; Astiarraga B; Chen Y; Alba M; Holst J; Ferrannini E
J Clin Endocrinol Metab; 2012 Aug; 97(8):2818-26. PubMed ID: 22685234
[TBL] [Abstract][Full Text] [Related]
32. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
Alsalim W; Göransson O; Carr RD; Bizzotto R; Tura A; Pacini G; Mari A; Ahrén B
Diabetes Obes Metab; 2018 Apr; 20(4):1080-1085. PubMed ID: 29227575
[TBL] [Abstract][Full Text] [Related]
33. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
[No Abstract] [Full Text] [Related]
34. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Stevens JE; Horowitz M; Deacon CF; Nauck M; Rayner CK; Jones KL
Aliment Pharmacol Ther; 2012 Aug; 36(4):379-90. PubMed ID: 22738299
[TBL] [Abstract][Full Text] [Related]
35. Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis.
Aitken ML; Szkudlinska MA; Boyko EJ; Ng D; Utzschneider KM; Kahn SE
Diabetologia; 2020 May; 63(5):1055-1065. PubMed ID: 31993716
[TBL] [Abstract][Full Text] [Related]
36. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic enzyme supplementation improves the incretin hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a randomized crossover trial.
Perano SJ; Couper JJ; Horowitz M; Martin AJ; Kritas S; Sullivan T; Rayner CK
J Clin Endocrinol Metab; 2014 Jul; 99(7):2486-93. PubMed ID: 24670086
[TBL] [Abstract][Full Text] [Related]
38. Hypoglycemia in cystic fibrosis during an extended oral glucose tolerance test.
Armaghanian N; Hetherington J; Parameswaran V; Chua EL; Markovic TP; Brand-Miller J; Steinbeck K
Pediatr Pulmonol; 2020 Dec; 55(12):3391-3399. PubMed ID: 32955169
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
40. Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease.
Jørgensen MB; Idorn T; Rydahl C; Hansen HP; Bressendorff I; Brandi L; Wewer Albrechtsen NJ; van Hall G; Hartmann B; Holst JJ; Knop FK; Hornum M; Feldt-Rasmussen B
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31608934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
